The rationale was that resistance to the MEK inhibitor by reactivating the pathway could be blunted by also blocking downstream with the CDK4/6 inhibitor, similar to combined BRAF and MEK inhibition in melanoma [28]. The gene discussed is BRAF; the disease is melanoma.